Dengue Envelope-1 & 3
Description
The E.coli derived recombinant 58kDa protein is a genetically engineered peptide which is derived from Dengue Type-1 and 3 to be expressed as a fused envelope, each part in this fusion contains 170 a.a (positions 46-217), it is used in ELISA assay. This fusion protein is connected to a 6xHis Tag. Dengue Type-1 and 3 is purified by proprietary chromatographic technique.
Product Specs
Product Science Overview
Dengue virus (DENV) is a mosquito-borne virus that causes dengue fever, a significant public health concern in tropical and subtropical regions. The virus belongs to the genus Flavivirus and has four distinct serotypes: DENV-1, DENV-2, DENV-3, and DENV-4. Each serotype can cause dengue fever, and infection with one serotype provides lifelong immunity to that serotype but not to the others. This article focuses on the recombinant protein known as Dengue Virus Subtype 1 & 3 fused Envelope 58kDa.
The envelope (E) protein of the dengue virus is a critical component for viral entry into host cells. It is responsible for binding to the host cell receptors and facilitating membrane fusion. The E protein is also the primary target for neutralizing antibodies, making it a key focus for vaccine development .
The recombinant Dengue Virus Subtype 1 & 3 fused Envelope 58kDa protein is a fusion of the envelope proteins from DENV-1 and DENV-3. This fusion protein is designed to elicit an immune response that can provide protection against multiple serotypes of the dengue virus. The 58kDa size indicates the molecular weight of the protein, which is a result of the combined sequences from the two serotypes .
Recombinant proteins are typically produced using various expression systems, such as bacterial, yeast, insect, or mammalian cells. The choice of expression system depends on factors like the complexity of the protein, post-translational modifications, and yield requirements. For the Dengue Virus Subtype 1 & 3 fused Envelope 58kDa protein, a common approach is to use baculovirus-insect cell expression systems due to their ability to produce high yields of properly folded and functional proteins .
The purification process involves several steps to ensure the recombinant protein is of high purity and suitable for research or vaccine development. Techniques such as affinity chromatography, ion exchange chromatography, and size-exclusion chromatography are commonly used to achieve this .
The primary application of the Dengue Virus Subtype 1 & 3 fused Envelope 58kDa recombinant protein is in vaccine development. Given the challenges in creating a vaccine that provides balanced protection against all four dengue serotypes, recombinant proteins offer a promising approach. By combining envelope proteins from different serotypes, researchers aim to develop a vaccine that can induce a broad and effective immune response .
Additionally, this recombinant protein can be used in diagnostic assays to detect antibodies against dengue virus in patient samples. It can also serve as a tool for studying the immune response to dengue virus and for screening potential antiviral compounds .
